MARBURG

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, January 7, 2021
Branches of biology, Chemistry, Natural sciences, Neuraminidase inhibitors, Carbohydrate chemistry, Acetamides, Guanidines, BioCryst Pharmaceuticals, Peramivir, Neuraminidase, Viral neuraminidase, Influenza

The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each stock option has a 10-year term and is subject to the terms and conditions of BioCrysts Inducement Equity Incentive Plan and a stock option agreement covering the grant.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

AIkido Pharma Inc. Executes Licensing Agreement for Psilocybin for Cancer Applications

Retrieved on: 
Wednesday, January 6, 2021
Psychoactive drugs, Entheogens, Mycotoxins, Organophosphates, Psilocybin, Organic compounds

NEW YORK, Jan. 6, 2021 /PRNewswire/ --AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applications.

Key Points: 
  • NEW YORK, Jan. 6, 2021 /PRNewswire/ --AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applications.
  • Research has shown psilocybin to have potential to treat a range of psychiatric and behavioral disorders, notably, cancer-related depression and anxiety.
  • Our license covers the use of psilocybin to treat both cancer and cancer side-effects and we believe this to be an expanding area for treatment."
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.

BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 6, 2021
Branches of biology, Neuraminidase inhibitors, Chemistry, Life sciences, Carbohydrate chemistry, BioCryst Pharmaceuticals, Acetamides, Guanidines, Peramivir, Neuraminidase, Viral neuraminidase, Influenza

RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Wednesday, January 13, 2021 at 11:40 a.m.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Wednesday, January 13, 2021 at 11:40 a.m.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.
  • For more information, please visit the Companys website at www.biocryst.com.

GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference

Retrieved on: 
Tuesday, January 5, 2021
Biotechnology Innovation Organization, Articles

GeoVax Also Participating in BIO@JPM During J.P. Morgan Week 2021

Key Points: 
  • GeoVax Also Participating in BIO@JPM During J.P. Morgan Week 2021
    ATLANTA, GA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc .
  • (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, announced today that Chairman, President and CEO David Dodd will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021.
  • The presentation will be available for on-demand listening beginningat 6:00 AM Eastern Time on Monday, January 11, 2021, through close of business January 14, 2021.
  • The Company also announced that it will participate in virtual one-on-one meetings with registered biopharmaceutical companies, investors and other interested parties through the one-on-one partnering system hosted by the Biotechnology Innovation Organization (BIO) during the J.P. Morgan conference week January 11-15, 2021.

Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine

Retrieved on: 
Tuesday, January 5, 2021
Medical specialties, Health, Medicine, Virology, Vaccines, Vaccination, Vaccine, Influenza vaccine, Virus, Attenuated vaccine, Influenza research

Emergex also has programmes in development for a universal Influenza vaccine and a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine and a Chikungunya vaccine.

Key Points: 
  • Emergex also has programmes in development for a universal Influenza vaccine and a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine and a Chikungunya vaccine.
  • The Company also has a collaboration in place with Brazil-based Bio-Manguinhos/Fiocruz for the development of several vaccine candidates, including a potential vaccine for COVID-19.
  • Background to Emergex Vaccine Approach:
    Both nave T-Cells and memory T-Cells are activated in an acute viral infection via trogocytosis (or cross-dressing).
  • It has one of Brazils largest public laboratories for vaccine production - the Immunobiological Technology Institute (Bio-Manguinhos).

Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine

Retrieved on: 
Tuesday, January 5, 2021
Medical specialties, Health, Medicine, Virology, Vaccines, Vaccination, Vaccine, Influenza vaccine, Virus, Attenuated vaccine, Influenza research

Emergex also has programmes in development for a universal Influenza vaccine and a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine and a Chikungunya vaccine.

Key Points: 
  • Emergex also has programmes in development for a universal Influenza vaccine and a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine and a Chikungunya vaccine.
  • The Company also has a collaboration in place with Brazil-based Bio-Manguinhos/Fiocruz for the development of several vaccine candidates, including a potential vaccine for COVID-19.
  • Background to Emergex Vaccine Approach:
    Both nave T-Cells and memory T-Cells are activated in an acute viral infection via trogocytosis (or cross-dressing).
  • It has one of Brazils largest public laboratories for vaccine production - the Immunobiological Technology Institute (Bio-Manguinhos).

BioCryst Provides Update on Galidesivir Program

Retrieved on: 
Tuesday, December 22, 2020
Antiviral drugs, Nucleosides, Ebola, Galidesivir, Biology, Life sciences, Medical specialties, Biodefense, National Institute of Allergy and Infectious Diseases, Broad-spectrum antiviral drug, BioCryst Pharmaceuticals

We are encouraged by the first patient data with galidesivir and the growing body of evidence that galidesivir could be an important broad-spectrum antiviral.

Key Points: 
  • We are encouraged by the first patient data with galidesivir and the growing body of evidence that galidesivir could be an important broad-spectrum antiviral.
  • We appreciate the governments continued investment to investigate galidesivir as a biodefense drug, said Jon Stonehouse, chief executive officer of BioCryst.
  • BioCryst is engaged in ongoing discussions with NIAID to define specific further galidesivir studies that NIAID would support.
  • This press release contains forward-looking statements, including statements regarding BioCrysts plans and expectations for its galidesivir development program.